The shares of this microcap company jumped 5 percent on the NSE after announcing its strong quarterly result. The stock was recently listed in June.
With a market capitalization of Rs. 29.16 crores, Vilin Bio Med Ltd shares opened today’s trading on a positive note. The share hit a high of Rs. 20.90 making a gain of around 5 percent and currently trading at the same price.
Such a positive movement was observed after the company announced its H1 FY24 results. The company’s revenue marginally decreased by 7 percent from Rs. 8.21 crores during H2 FY23 to Rs. 7.64 crores in H1 FY24. On a contrasting note, the net profit increased 10 percent from Rs. 69.37 lakhs to Rs. 76.9 lakhs during the same period.
Comparing these metrics on a YoY basis, the revenue magnified by 86 percent from Rs. 4.10 crores during H1 FY23 to Rs. 7.64 crores in H1 FY24. In addition, the net profit zoomed by 40 percent from Rs. 55.12 lakhs to Rs. 76.19 lakhs during the same timeframe.
Looking at the important ratios, the return on equity (RoE) increased from 0.46 percent during FY 21-22 to 13.78 percent in FY22-23. Furthermore, the return on capital employed improved from 0.72 percent to 17.17 percent during the same time horizon.
According to the latest shareholding pattern, Promoters have a 64.52 percent stake in the company, and the remaining 35.48 percent is with the Public or Retail Investors.
Headquartered in Secunderabad, Vilin Bio Med Ltd was incorporated in the year 2003. Vilin Bio Med Ltd is engaged in the manufacturing of pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules, and nutritional Food supplements.
Written By Vaibhav Patil
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
